Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (4955)	5/20/1998 3:47:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 9719

Rman, what are your predictions for Genzyme's revenues and earnings? What do you think makes Genzyme cheap now? I sold my Genzyme last week and bought back again yesterday, so I like to hear that others think Genzyme might be a good deal, but why is it a good deal? I think Genzyme's earnings will continue to be solid, but not appreciate in any spectacular fashion. The potentially special thing about the company is its earnings in the face of a maturing pipeline. The positive aspect of the recent convertible sale is that there is now lots of money for GENZL and GZTC to tap if they need to.

To: Rocketman who wrote (4955)	5/20/1998 8:10:00 PM
From: Cytokine1	Respond to of 9719

Rman--I have reviewed the margin number and it seems ok (disclaimer--I could be missing something). The last time we had a big error, I had added instead of subtracted from the margin. I checked everything from 4/1/98 to now and the plusses and minuses seem correct--remember the QGEN short sale covering only shows the profit, not the entire sale amount. CYTO now a penny stock, what a woof-woof. A buyout candidate? $55M market cap (we were in it when it had a nearly $300M cap). Do they really have anything worthwhile, or not? The market has said no, no, no. Looking at a '50 Chebby hardtop Deluxe, much cheaper than the Caddy. Later, C1.

To: Rocketman who wrote (4955)	5/20/1998 8:21:00 PM
From: Cytokine1	Read Replies (1) \| Respond to of 9719

VD's MODEL PORTFOLIO 5/20/98 Change -$5532 DOWN -2.39% Started 4/9/97, $100K . INDEX ^IXB DOWN -0.93% YTD EQUITY CHANGE 24.5% a # CURRENT DAILY CURRENT COST TOTAL %GAIN/ % OF SYMBOL SHRS PRICE CHANGE %CHG VALUE SHR COST LOSS TOTAL ======= ======= ======= ======= ======= ======= ======= ======= ======= ======= CLTR 1000 29.19 -2.31 -7.34% 29188 10.88 10875 168.4% 12.9% GZTC 2770 9.88 -0.25 -2.47% 27354 7.737 21432 27.6% 12.1% INCY 1000 36.22 -1.19 -3.17% 36219 29.41 29409 23.2% 16.0% GENZ 830 27.88 -0.34 -1.22% 23136 25.17 20893 10.7% 10.3% BGEN 200 45.25 -0.75 -1.63% 9050 35.88 7175 26.1% 4.0% SEPR 146 43.75 -0.50 -1.13% 6388 37.16 5426 17.7% 2.8% DURA 300 27.69 0.00 0.00% 8306 24.63 7388 12.4% 3.7% AVIR 1000 28.56 -0.94 -3.18% 28563 27.88 27875 2.5% 12.7% MLNM 300 18.38 -0.06 -0.34% 5513 18.63 5588 -1.3% 2.4% LGNDW 3000 9.00 0.25 2.86% 27000 8.75 26250 2.9% 12.0% REGN 1000 9.44 -0.31 -3.21% 9438 12.00 12000 -21.4% 4.2% ABSC 1000 8.19 -0.44 -5.07% 8188 11.19 11189 -26.8% 3.6% GENZL 1000 7.38 0.13 1.72% 7375 10.36 10363 -28.8% 3.3% STOCK ______ ______ ______ ______ 225715 195861 15.2% 100.0% SHORT SALE CREDIT ______ ______ MARGIN MTCE. EQUITY 53.8% MIN 30% (104357) BUYING POWER $ ______ 17000 EQUITY (NAV) ______ ______ ______ 121358 100000 21.4% ^IXB INDEX 329.11 -3.08 -0.93% 302.42 8.8% NOTES: OPEN orders subject to available buying power--- Open limit buy order, min 50 shrs, max 154 shrs SEPR @ 38 or less Open limit buy order, 3000 shrs MOGN @ $8.00 or less Open limit sell order, 260 shrs GENZ @ $35 5/18/98 -8437.5 GENZ bought 300 @ 28.125 5/14/98 -5214 ABSC bought 600 @ 8.69 5/13/98 -15375 AVIR bought 500 @ 30.75 5/13/98 -2660 INCY bought 5/13/98 70 @ $38 5/13/98 34875 MOGN sold 3000 @ $11.625, gain 134% 5/11/98 -8468.75 INCY bought 5/11/98, 250 additional @ $33.875 5/1/98 2125 GSII sold 500 @ 4.25, gain $0, broke even.

To: Rocketman who wrote (4955)	5/22/1998 9:14:00 AM
From: bluejeans	Read Replies (1) \| Respond to of 9719

cytogen is filing lawsuit today against Merck .Merck will cease marketing Quadramet On May 25th. PR-CYTOGEN SUES DUPONT MERCK FOR BREACH OF QUADRAMET(R) LICENSE AGREEMEN PRINCETON, N.J., May 22, 1998 - CYTOGEN Corporation (Nasdaq: CYTO) announced today that it filed suit in the Superior Court of the State of New Jersey against The DuPont Merck Pharmaceutical Company asserting that DuPont Merck failed to fulfill its obligations under an agreement to market Quadramet(R), CYTOGEN's product for the relief of bone pain caused from cancer which has spread to the bone. DuPont Merck had notified CYTOGEN that it would cease marketing Quadramet on Monday, May 25, 1998 on the grounds that CYTOGEN allegedly breached the license agreement between CYTOGEN and DuPont Merck dated December 20, 1994. CYTOGEN believes DuPont Merck's allegations are wholly unsupportable, and has filed the lawsuit in an effort to enforce DuPont Merck's obligation to market Quadramet(R). John Bagalay, President and Chief Executive Officer of CYTOGEN said, "we are extremely concerned about any disruption of patient therapy which may be caused by these marketing actions and are aggressively pursuing options to assure the continued delivery of Quadramet(R) therapy to patients with bone pain." Under the terms of the license agreement, DuPont Merck has the responsibility to manufacture and market Quadramet(R) in the United States. CYTOGEN is responsible for certain regulatory approvals and clinical development of Quadramet(R) for other indications. Quadramet(R) was cleared for marketing by the U.S. Food and Drug Administration in March of 1997 for the treatment of bone pain associated with cancers that have spread to the bone. In May 1997, DuPont Merck began marketing Quadramet(R). CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostics and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial scale biologic manufacturing. Information in this press release, which is not historical, is forward looking and involves risks and uncertainties. Actual results may differ materially, for reasons discussed in the Company's filings with the Securities and Exchange Commission, including risks related to unanticipated expenses which may reduce the Company's ability to achieve maximum efficiencies from the change in business strategies, the ability to find a suitable partner for further development of the technology, and commercial acceptance of the Company's products. SOURCE CYTOGEN Corporation -0- 05/22/98 /CONTACT: Donald Crane of CYTOGEN Corporation, 609-520-3062; or Angela M. Bitting of Russell-Welsh, Inc., 650-312-0700, ext. 15/ (CYTO) CO: CYTOGEN Corporation; DuPont Merck Pharmaceutical Company ST: New Jersey IN: HEA MTC SU: LIC